Xenon Pharmaceuticals Inc.
Clinical trials sponsored by Xenon Pharmaceuticals Inc., explained in plain language.
A clinical-stage biopharmaceutical company developing neurology therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill could tame focal seizures when other drugs fail Results expected Oct 2026 (estimated) 🚀 Make-or-break
- New depression drug tested for Long-Term safety and effectiveness Results expected Jan 2027 (estimated) May already have reported ↗
- New seizure drug shows promise in late-stage trial Results expected Apr 2027 (estimated)
- New depression pill could lift the fog: phase 3 trial underway Results expected May 2027 (estimated) May already have reported ↗ 🚀 Make-or-break
-
New epilepsy drug XEN1101 tested for long-term seizure control
Disease control By invitation onlyThis study tests the long-term safety and effectiveness of XEN1101 (azetukalner) in 880 adults with focal or tonic-clonic seizures. Participants who completed earlier studies will take XEN1101 capsules for up to 6 years. Researchers will track side effects and changes in monthly …
Phase 3 • Sponsor: Xenon Pharmaceuticals Inc. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New depression drug tested for Long-Term safety and effectiveness
Disease control By invitation onlyThis study looks at the long-term safety and effectiveness of azetukalner in adults with major depressive disorder. Participants must have successfully completed a previous phase 3 study of this drug. The goal is to monitor side effects and track changes in depression symptoms ov…
Phase 3 • Sponsor: Xenon Pharmaceuticals Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug shows promise for Long-Term bipolar depression control
Disease control By invitation onlyThis Phase 3 study tests the long-term safety and effectiveness of azetukalner, a daily pill, in 400 adults with bipolar I or II depression who previously completed a related study. Participants take the drug for 52 weeks, and researchers track side effects, mood changes, and qua…
Phase 3 • Sponsor: Xenon Pharmaceuticals Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC